ストックスクリーナーアプリを入手
157.94
1.28%
-2.05
アフターアワーズ：
157.29
-0.65
-0.41%
前日終値:
$159.99
開ける：
$158.19
24時間の取引高:
1.54M
Relative Volume:
1.31
時価総額：
$23.15B
収益：
$9.61B
当期純損益:
$1.62B
株価収益率:
8.5977
EPS:
18.37
ネットキャッシュフロー:
$1.77B
1週間 パフォーマンス:
-8.19%
1か月 パフォーマンス:
-16.94%
6か月 パフォーマンス:
-31.50%
1年 パフォーマンス:
-30.73%
1日の値動き範囲:
$157.40
$160.11
1週間の範囲:
$157.40
$175.86
52週間の値動き範囲:
$157.40
$268.30
Biogen Inc Stock (BIIB) Company Profile
BIIB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BIIB | 157.94 | 23.15B | 9.61B | 1.62B | 1.77B | 18.37 |
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 - Benzinga
Needham downgrades Biogen on slow growth of Alzheimer's drug By Investing.com - Investing.com Canada
Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales (NASDAQ:BIIB) - Seeking Alpha
Opuviz is latest EC-approved ophthalmology biosimilar - The Pharma Letter
Biogen (NASDAQ:BIIB) Sets New 12-Month LowShould You Sell? - MarketBeat
Biogen (NASDAQ:BIIB) Downgraded to "Hold" Rating by Needham & Company LLC - MarketBeat
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ - GlobeNewswire
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ - Biogen | Investor Relations
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ - GlobeNewswire Inc.
Analyst recommendations: Biogen, HP, Moderna, Shell... - Marketscreener.com
Biogen Inc. (NASDAQ:BIIB) Shares Sold by KBC Group NV - MarketBeat
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? - Insider Monkey
Top 10 Alzheimer’s Disease Therapeutics Companies | Provides Best TreatmentsMarket.us Media - Market.us Media - United States Market News
Seizert Capital Partners LLC Has $2.13 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Mizuho Securities USA LLC - MarketBeat
ING Groep NV Has $3.81 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Impax Asset Management Group plc Has $7.52 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Los Angeles Capital Management LLC Buys Shares of 4,282 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
How a Biogen drug set the stage for a new biotech targeting ALS - BioPharma Dive
BIIB (Biogen) Total Inventories : $2,469 Mil (As of Sep. 2024) - GuruFocus.com
Biogen Unusual Options Activity - Benzinga
Cornercap Investment Counsel Inc. Invests $1.37 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe - Yahoo Finance
Biogen (NASDAQ:BIIB) Now Covered by Analysts at Wolfe Research - MarketBeat
Citigroup Upgrades Biogen (NASDAQ:BIIB) to Hold - MarketBeat
Prime Capital Investment Advisors LLC Sells 5,201 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Purchases 9,254 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment) - ACN Newswire
European Agency Switches to Recommending New Alzheimer's Drug - Nippon.com
Eisai wins over European regulators on Alzheimer’s drug Leqembi - BioPharma Dive
Leqembi, which was developed by US multinational Biogen and Japanese-based Eisai, is the brand name of an active substance called lecanemab that is used to treat adults with mild memory and cognitive problems resulting from the early stages of the com - Islander News.com
EU regulator backs Eisai-Biogen Alzheimer’s drug - The Hindu
NATIONWIDE TV COMMERCIAL LAUNCHED IN JAPAN TO RAISE AWARENESS ABOUT MCI (MILD COGNITIVE IMPAIRMENT) - Eisai
Biogen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall - Boston Herald
European committee takes a second look at Alzheimer's drug and now says it should be approved - The Washington Post
Leqembi Secures EMA Thumbs Up For Narrower Indication - Citeline
EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection - Reuters.com
US Biogen Leqembi EU - Bluefield Daily Telegraph
Eli Lilly, Biogen, and 3 Other Healthcare Stocks to Buy in a Beaten-Up Sector - Barron's
U.S. STOCKS Talen Energy, Biogen, Ovintiv - XM
EMA committee rethinks stance and recommends Leqembi for Alzheimer’s disease - Pharmaceutical Technology
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease - PR Newswire
Biogen stock rises after E.U. regulator reverses gloomy view of Alzheimer’s drug - MarketWatch
EU drugs regulator recommends Alzheimer’s drug from Eisai-Biogen - 1470 & 100.3 WMBD
Eisai and Biogen's Alzheimer's drug gets positive CHMP opinion - Investing.com
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease - Biogen | Investor Relations
Eisai-Biogen Alzheimer's Drug Gets Key EU Panel Backing, Shows 31% Decline Reduction | BIIB Stock News - StockTitan
Biogen stock gains as EU backs Alzheimer’s drug (BIIB:NASDAQ) - Seeking Alpha
Peeling Back The Layers: Exploring Biogen Through Analyst Insights - Benzinga
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
1.03%
1.71%
大文字化:
|
ボリューム (24 時間):